How [14C]-JNT-517 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Male Participants

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study ID
NCT07573449
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
MALE
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • [14C]-JNT-517 — DRUG
    Suspension

Study Details

The purpose of this study is to determine the absorption, metabolism and excretion of \[14C\]-JNT-517 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants following a single oral administration.

Key Dates

First listed
May 7, 2026
Start date
Jan 22, 2024
Status verified
Apr 2026
Primary completion
Jan 22, 2025
Completion
Feb 27, 2025

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: [14C]-JNT-517
    Participants receive a single dose of \[14C\]-JNT-517, orally, on Day 1

Primary Outcome Measure

Total Radioactivity Recovery (fet1-t2) in Urine and Feces [ Time Frame: Up to Day 9 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research Unit Inc.MadisonWisconsin53704-

Find similar trials in Madison, WI

By research site
Fortrea Clinical Research Unit Inc.· Madison, WI

Related Studies